Biopolym. Cell. 1997; 13(5):345-351.
http://dx.doi.org/10.7124/bc.000495
Огляди
Фактор переносу як модулятор клітинної імунної відповіді
1Любченко Т. А., 1Голєва О. Г., 1Холодна Л. С.
  1. Київський національний університет імені Тараса Шевченка
    вул. Володимирська 64, Київ, Україна, 01033

Abstract

Огляд присвячено фактору переносу (Transfer Factor) – імуномодулятору природного походження, який впливає на клітинно-опосередкований імунітет. Цей компонент низькомолекулярного діалізованого екстракту лейкоцитів застосовується на сьогодні як стимулятор клітинно-опосеред­кованої ланки імунної відповіді при багатьох захворюваннях, що супроводжуються імуноде­фіцитами, спричиненими бактеріальними, вірусними, грибковими інфекціями та малігнізацісю. У той же час питання про його хімічну структуру та механізми дії залишаєтья не повністю з'ясованим. Проаналізовано сучасні дані з цієї проблеми.
Повний текст: (PDF, українською)

References

[1] Lawrence HS. The cellular transfer of cutaneous hypersensitivity to tuberculin in man. Proc Soc Exp Biol Med. 1949;71(4):516-22.
[2] Lawrence HS. The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes. J Clin Invest. 1955;34(2):219-30.
[3] Fudenberg HH, Fudenberg HH. Transfer factor: past, present and future. Annu Rev Pharmacol Toxicol. 1989;29:475-516.
[4] Wilson GB, Paddock GV, Fudenberg HH. Bovine «Transfer Factor»: an oligoribonucleotide which initiates an­ tigen-specific lymphocyte responsiveness. Thymus. 1982; 4: 335-340.
[5] Kirkpatrick CN. Purification and composition of transfer factors. Mol Immunol. 1992. 2(29): 167-82.
[6] Rozzo SI, Boymel J, Kirkpatrick CH. Composition and purification of transfer factors. Recent advances of transfer factor and dialyzable leukocyte extracts. Eds T. Fujisawa et al-Tokyo: Mazuren Co. Ltd., 1992: 11-22
[7] Recent advances in transfer factor and dialyzable leukocyte extracts. Eds T. Fujisawa et al. Tokyo: Mazuren Co., Ltd., 1992. 267 p.
[8] Karhum?ki E, Marnela KM, Krohn K. Chromatographic and enzymatic effects on transfer factor-like activity from human leukocytes and porcine spleen dialysate. Int J Biochem. 1988;20(10):1067-72.
[9] Rosso di San Secondo VE, Lugaro G, Sirchia G. Dialyzable leukocyte extract: partial purification of low-molecular-weight factors suppressing and enhancing lymphocyte transformation. J Exp Pathol. 1987 Summer;3(4):425-7.
[10] Sipka S, Schr?der I, Brazsnikova NA. Effect of different fractions of dialyzable leukocyte extract--transfer factor--on the chemiluminescence of human phagocytes. Allergol Immunopathol (Madr). 1987;15(3):143-4.
[11] Kirkpatrick CH, Rozzo SJ, Mascali JJ. Murine transfer factor. III. Specific interactions between transfer factor and antigen. J Immunol. 1985;135(6):4027-33.
[12] Kirkpatrick CH, Rozzo SJ, Mascali JJ, Merryman CF. Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. J Immunol. 1985;134(3):1723-7.
[13] Wilson GB, Johnson HT, Jr, Halushka PV, Garner BP, Berkaw MN, Powers RE, et al. Contribution of prostaglandins to the biological activity of dialyzable leukocyte extracts containing transfer factor activity . Immune regulators and transfer factor. Eds A. Khan, C. H. Kirkpatrick, N. O. HilL-New York: Acad, press, 1979: 137-49.
[14] Wilson GB, Welch TM, Knapp DR, Horsmanheimo A, Fudenberg HH. Characterization of Tx, an active subfraction of human dialyzable transfer factor. I. Identification of the major component in TFg, a precursor of Tx, as hypoxanthine. Clin Immunol Immunopathol. 1977;8(3):551-68.
[15] Burger DR, Vandenbark AA, Daves D, Anderson WA Jr, Vetto RM, Finke P. Nicotinamide: suppression of lymphocyte transformation with a component identified in human transfer factor. J Immunol. 1976;117(3):797-801.
[16] Fudenberg HH. Dialyzable transfer factor in the treatment of human osteosarcoma: an analytic review. Ann N Y Acad Sci. 1976;277(00):545-57.
[17] Rosso VEM, Secondo DS, Pontecucci P et al. Purification of an immunosupressive factor from dialyzable leukocyte extracts. Recent advances of transfer factor and dialyzable leukocyte extracts. Eds T. Fujisawa et al. Tokyo: Mazuren Co. Ltd., 1992: 73-9.
[18] Cohen L, Holzman RS, Valentine FT, Lawrence HS. Requirement of precommitted cells as targets for the augmentation of lymphocyte proliferation by leukocyte dialysates. J Exp Med. 1976;143(4):791-804.
[19] Lawrence HS, Borkowsky W. Transfer Factor: current status and future prospects. Xth Int. Symp. on Transfer Factor (22nd-24th June 1995): Abstrs. Bologna, 1995: 3.
[20] Fen ZZ. The effects of some biochemical products on proliferation of bone marrow cells in mice. Xth Int. Symp. on Transfer Factor (22nd-24th June 1995): Abstrs. Bologna, 1995.: 8.
[21] Barnet K, Vacek A, Cech K, Pekarek J. The effect of fractions of DLE-TF on GM-progenitors of haemopoetic cells in vitro II Xth Int. Symp. on Transfer Factor (22nd-24th June 1995): Abstrs. Bologna, 1995.: 9.
[22] Gottlieb AA, Farmer JL, Matzura CT, Hester RB, Rosenberg JS. Modulation of human T cell production of migration inhibitory lymphokines by cytokines derived from human leukocyte dialysates. J Immunol. 1984;132(1):256-60.
[23] N?k?m K, Kalm?r L, Gergely P, Kelemen G, Fekete B, L?ng I, L?vai J, Petr?nyi GY. In vitro effect of transfer factor on active rosettes and leucocyte migration of patients with cancer. Clin Exp Immunol. 1977;27(3):416-20.
[24] Dupont B, Ballow M, Hansen JA, Quick C, Yunis EJ, Good RA. Effect of transfer factor therapy on mixed lymphocyte culture reactivity. Proc Natl Acad Sci U S A. 1974;71(3):867-71.
[25] L?ng I, N?k?m K, Gergely P, Petr?nyi G. Effect of in vivo and in vitro treatment with dialyzable leukocyte extracts on human natural killer cell activity. Clin Immunol Immunopathol. 1982;25(1):139–44.
[26] N?k?m K, L?ng I, T?r?k K, Kalm?r L, Gergely P, Petr?nyi G. Effects of therapy with dialyzable leukocyte extracts containing transfer factor activity on antibody-dependent cytotoxic activity in humans. Clin Immunol Immunopathol. 1979;13(4):407–12.
[27] Kirkpatrick CN, Burger DR, Lawrence II.S. Immunobiology of Transfer Factor. New York: Acad, press, 1983. 283 p.
[28] Dortling P, Schroeder I. Effect of dialyzable leukocyte extract at its different fractions on the production of H202 and IL-1 by macrophages. Leukocyte dialyzates and Transfer Factor . Eds V. Mayer, J. Borvak. Bratislava: Inst. Virol. Slovak. Acad. Sci., 1987: 141-5.
[29] Cheredeev AYa. Effect of low molecular dialysate leukocyte immune response of mice to SRBC. Immunologiia. 1983; 5: 53-5.
[30] Kvizhinadze LR, Semenkov VF, Cheredeev AN, Batyrbekov AA, Svirezheva MN. [Effect of low molecular-weight leukocyte dialysate on endogenous colony-formation in the mouse]. Biull Eksp Biol Med. 1982;94(11):63-5.
[31] Cheredeev AYa, Kvizgynadze LR, Solov'ev VV, Ganina VYa. Effect of the low molecular weight extract on immune cells and their co-operation with the development of the immune response of mice to SRBC. Immunologiia. 1986; 4: 34-6.
[32] N?k?m K, Fudenberg HH, M?ndi B, L?ng I, Gergely P, Petr?nyi G. Resynthesis of trypsinized sheep red blood cell receptors on human lymphocytes: comparison of the effects of immunopotentiators of biological and synthetic origin in vitro. Immunopharmacology. 1981;3(1):31-9.
[33] Gallin JI, Kirkpatrick CH. Chemotactic activity in dialyzable transfer factor. Proc Natl Acad Sci U S A. 1974;71(2):498-502.
[34] Byers VS, Levin AS, Hackett AJ, Fudenberg HH. Tumor-specific cell-mediated immunity in household contacts of cancer patients.. J Clin Invest. 1975;55(3):500-13.
[35] Jirsch DW. Immunological Engineering. 1978; Springer Netherlands
[36] Kirkpatrick CH, Greenberg LE. Treatment of chronic mucocutaneous candidiasis with Transfer Factor. Immune regulators and Transfer Factor. Eds A. Khan, C. H. Kirkpatrick, N. O. Hill. New York: Acad, press, 1979; 97-105.
[37] Littman BH, Rocklin RE, Parkman R, David JR. Transfer factor treatment of chronic mucocutaneous candidiasis: requirement for donor reactivity to candida antigen. Clin Immunol Immunopathol. 1978;9(1):97-110.
[38] Tsang KY, Fudenberg II. Transfer Factor and other T cell derived factor (non-LKs). Springer Seminars in Immuno­pathol. 1986; 8: 4-12,
[39] Lee WM, Holley HP, Stewart J, Galbraith GMP. Refractory esophageal candidiasis associated with a low molecular weight plasma inhibitor of T-lymphocyte function. Am J Med Sci. 1986;292(1):47–52.
[40] Rytter M, Sch?nborn C, Lohrisch I, Haustein UF. [Chronic mucocutaneous candida mycosis (CMCC) caused by a T-cell defect]. Z Gesamte Inn Med. 1986;41(7):214-6.
[41] Veselsk? A, Svejda J, Richter J. [Mucosal candidiasis]. Cas Lek Cesk. 1991;130(18-19):561-2.
[42] Catanzero A, Spitler IE. Clinical and immunological results of TF therapy in coccidiomycosis. Transfer Factor: Basic properties and clinical applications. Eds MS Asher, AA Gottlieb, CH. Kirkpatrick. New York: Acad, press, 1976. p. 477-94.
[43] Snirc J, Mikula I, Pistl J. The induction of specific protection against Actinobacillus pleuropneumoniae infection by specific DLE. Acta Microbiol Hung. 1993;40(4):325-33.
[44] Radosevich JK, Scott GH, Olson GB. Delayed-type hypersensitivity responses induced by bovine colostral components. Am J Vet Res. 1985;46(4):875-8.
[45] Josten C, Muhr G, Sistermann R. First experience with immunomodulation in septic shock. Prog Clin Biol Res. 1989;308:989-94.
[46] Bullock WE, Fields JP, Brandriss MW. An evaluation of transfer factor as immunotherapy for patients with lepromatous leprosy. N Engl J Med. 1972;287(21):1053-9.
[47] Hastings RC, Morales MJ. Preliminary results in the safety and efficacy of transfer factor in leprosy. Transfer Factor: basic properties and clinical applications. Eds M. S. Asher, A. A. Gottlieb, C. H. Kirkpatrick. New York: Acad, press, 1976: 465-76.
[48] Leser PG, Margarido L, Belda W, Sartori SG, Hares WA, Freire CA, Fleury R, Montenegro MR, Leser W, Naspitz CK. Cell mediated immunity in patients with Virchowian hanseniasis before and after treatment with transfer factor. Hansenol Int. 1980;5(1):3-27.
[49] Pckarek Chech K, Barnet K. The clmican use of specific transfer factors. 7 Recent advances in Transfer Factor and dialyzable leukocyte extracts. Eds T. Fujisawa et al. Tokyo: Mazuren Co., Ltd., 1992: 256-63,
[50] Metcalf JF, John JF Jr, Wilson GB, Fudenberg HH, Harley RA. Mycobacterium fortuitum pulmonary infection associated with an antigen-selective defect in cellular immunity. Am J Med. 1981;71(3):485-92.
[51] Wilson GB, Metcalf JF, Fudenberg HH. Treatment of Mycobacterium fortuitum pulmonary infection with "transfer factor" (TF): new methodology for evaluating TF potency and predicting clinical response. Clin Immunol Immunopathol. 1982;23(2):478-91.
[52] Buchwald S, Perepechkina NP, Salov VF, Mats AN. [The local specific immune response to Staphylococcus aureus protein A in human tonsillar lymphoid tissue]. Zh Mikrobiol Epidemiol Immunobiol. 1985;(5):78-83.
[53] Human specific Transfer Factor of cell-mediated immunity to Staphylococcus antigen substances. Xth Int. Symp. on Transfer Factor (22nd-24th June 1995): Abstrs. Bologna, 1995: 14.
[54] The suppression of the T-effector and transfer factor by the Salmonella lypopolysaccharide. Xth Int. Symp. on Transfer Factor (22nd-24th June 1995): Abstrs. Bologna, 1995: 15.
[55] Lokaj J. [The dialysate of leukocyte homogenate in the treatment of sepsis]. Bratisl Lek Listy. 1988;89(8):586-90.
[56] Percopo V, Taddeo F, Cobellis L, Tesauro B. Immunostimulation in sepsis. Ann Ital Chir. 1994;65(1):45-7.
[57] Sharma MK, Anaraki F, Ala F. Preliminary results of transfer factor therapy of persistant cutaneous leishmania infection. Clin Immunol Immunopathol. 1979;12(2):183-90.
[58] Dundas SA, Clark A. The effect of transfer factor on lymph node morphology in murine toxoplasmosis. Br J Exp Pathol. 1986;67(2):181-90.
[59] Karhum?ki E, Ashorn R, Krohn K. Effect of human leukocyte and other tissue dialysates on Listeria resistance and phagocytosis in mice. Acta Pathol Microbiol Immunol Scand C. 1985;93(3):111-6.
[60] Mishra SS, Jaiswai TN. Transfer of delayed hypersen­ sitivity by dialysable lymphocyte extract from Listeria mo­ nocytogenes sensitized rabbits. Indian Vet J. 1992; 69(1): 1-4.
[61] de G?rgolas Hern?ndez-Mora M, Verdejo Morcillo C, Fern?ndez Guerrero ML. [Therapeutic approaches to cryptosporidiosis. A review of the literature]. Rev Clin Esp. 1993;193(6):322-8.
[62] Louie E, Borkowsky W, Klesius PH, Haynes TB, Gordon S, Bonk S, Lawrence HS. Treatment of cryptosporidiosis with oral bovine transfer factor. Clin Immunol Immunopathol. 1987;44(3):329-34.
[63] Zhang SH, Wang ZQ, Wang XZ et al. Experimental observations on the efficacy of specific transfer factor and immuno-ribonucleic acid against schistosome infection. Chi- Sheng-Chung-Hsueh-Yu-Chi-Sheng-Chung-Ping-Tsa-Chih. 1986; 4(1): 39-41.
[64] Carey JT, Lederman MM, Toossi Z, Edmonds K, Hodder S, Calabrese LH, Proffitt MR, Johnson CE, Ellner JJ. Augmentation of skin test reactivity and lymphocyte blastogenesis in patients with AIDS treated with transfer factor. JAMA. 1987;257(5):651-5.
[65] Carey JT, Lederman MM. Treatment of AIDS with transfer factor. JAMA. 1987;258(24):3515-6.
[66] Viza D, Lefesvre A, Patrasco M, Phillips J, Hebbrecht N, Laumond G, Vich JM. A preliminary report on three AIDS Patients treated with anti-HIV specific transfer factor. J Exp Pathol. 1987 Summer;3(4):653-9.
[67] G?ring HD, Ott D, Schwalm I, Ziemer A. [Cellular immune defect and transfer factor therapy in epidermolysis bullosa simplex of the Weber-Cockayne type]. Dermatol Monatsschr. 1988;174(1):10-3.
[68] Neequaye J, Viza D, Pizza G, Levine PH, De Vinci C, Ablashi DV, Biggar RJ, Nkrumah FK. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. Anticancer Res. 1990;10(5A):1183-7.
[69] Nkrumah FK, Pizza G, Neequaye J et al. Transfer factor in prevention of Burkitt's lymphoma relapses. Lymphokine Res. 1985; 4(3): 237-41.
[70] Shizawa Y, Shishido S, Kawabata Y. [An autopsied case of chronic active Epstein-Barr virus (EBV) infection with various symptom]. Kansenshogaku Zasshi. 1991;65(4):481-7.
[71] Pogodina VV, Levina LS, Perepechkina NP, Mats AN. [The effect of preparations of specific and nonspecific transfer-factor on the course of experimental tick-borne encephalitis]. Vopr Virusol. 1989;34(6):689-94.
[72] Song C, Li B, Wu W. Specific inducer factor purified from splenocytic dialyzates of goat immunized with Japanese encephalitis virus. Acta Virol. 1993;37(1):109.
[73] Iseki M, Aoyama T, Koizumi Y, Ojima T, Murase Y, Osano M. [Effects of transfer factor on chronic hepatitis B in childhood]. Kansenshogaku Zasshi. 1989;63(12):1329-32.
[74] Janout V, N?mecek V, Mazel J, Sedl?cek V. An outbreak of viral hepatitis B associated with transfer factor administration. J Hyg Epidemiol Microbiol Immunol. 1990;34(1):31-6.
[75] Mazzella G, Ronchi M, Villanova N, Mohamed AA, Pizza G, De Vinci C, Viza D, Roda E, Barbara L. Treatment of chronic B virus hepatitis with specific transfer factor. J Exp Pathol. 1987 Summer;3(4):421-3.
[76] Roda E, Viza D, Pizza G, Mastroroberto L, Phillips J, De Vinci C, Barbara L. Transfer factor for the treatment of HBsAg-positive chronic active hepatitis. Proc Soc Exp Biol Med. 1985;178(3):468-75.
[77] Stancek D, Hajnick? V, Blaskovicov? H, Sudov? J, Laktis K, Janota S, Jezek P. Transient increase of HBsAg levels following human IFN alpha treatment signalises the patient's response in chronic active hepatitis B. Acta Virol. 1990;34(5):457-66.
[78] Sumiyama K, Kobayashi M, Miyashiro E, Koike M. Combination therapy with transfer factor and high dose stronger neo-minophagen C in chronic hepatitis B in children (HBe Ag positive). Acta Paediatr Jpn. 1991;33(3):327-34.
[79] Pizza G, Meduri R, De Vinci C, Scorolli L, Viza D. Transfer factor prevents relapses in herpes keratitis patients: a pilot study. Biotherapy. 1994;8(1):63-8.
[80] Viza D, Vich JM, Phillips J, Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphokine Res. 1985 Winter;4(1):27-30.
[81] Viza D, Vich JM, Phillips J, Davies DA. Use of specific transfer factor for the prevention or the treatment of herpes infections in mice and in man. J Exp Pathol. 1987 Summer;3(4):407-20.
[82] Fudenberg FL. Ophthalmologic herpes zoster: Complete remission in six hours with dialyzable transfer factor. J Clin Lab Immunol. 1985; 18: 49-51.
[83] Busutti L, Blotta A, Mastrorilli M, Savorani GC, Pizza G, De Vinci C. Transfer factor adjuvant therapy in nonsmall-cell lung carcinoma. (NSCLC) after surgery and radiotherapy. J Exp Pathol. 1987 Summer;3(4):565-8.
[84] Fujisawa T, Yamaguchi Y, Kimura H, Arita M, Shiba M, Baba M. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn J Surg. 1984;14(6):452-8.
[85] Whyte RI, Schork MA, Sloan H, Orringer MB, Kirsh MM. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg. 1992;53(3):391-6.
[86] Fazio M, Negri L, Mastromatteo V et al. Osteosarcoma- specific transfer factor: preliminary clinical results. J Exp Pathol. 1987; 3(4): 250-4.
[87] Fudenberg H, Tsang KY. Theories and models in cellular transformation. Eds Santi et al. New York; London: Acad, press, 1985: 23-34.
[88] Gilchrist GS, Ivins JC, Ritts RE Jr, Pritchard DJ, Taylor WF, Edmonson JM. Adjuvant therapy for nonmetastatic osteogenic sarcoma: an evaluation of transfer factor versus combination chemotherapy. Cancer Treat Rep. 1978;62(2):289-94.
[89] Ivins JC, Ritts RE, Pritchard DJ, Gilchrist GS, Miller GC, Taylor WF. Transfer factor versus combination chemotherapy: a preliminary report of a randomized postsurgical adjuvant treatment study in osteogenic sarcoma. Ann N Y Acad Sci. 1976;277(00):558-74.
[90] Blume MR, Rosenbaum EH, Cohen RJ, Gershow J, Glassberg AB, Shepley E. Adjuvant immunotherapy of high risk stage I melanoma with transfer factor. Cancer. 1981;47(5):882-8.
[91] Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomized controlled trial of transfer factor in Stage II malignant melanoma. Cancer. 1983;51(2):269-72.
[92] Gonzalez RL, Wong P, Spitler LE. Adjuvant immunotherapy with transfer factor in patients with melanoma metastatic to lung. Cancer. 1980;45(1):57-63.
[93] Schwarz MA, Gutterman JU, Burgess MA, Heilbrun LK, Murphy WK, Bodey GP, Stone E, Turner-Chism V, Hersh EM. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan. Cancer. 1980;45(10):2506-15.
[94] Miller LL, Spitler LE, Allen RE, Minor DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer. 1988;61(8):1543-9.
[95] Goldenberg GJ, Brandes LJ. In vivo and in vitro studies of immunotherapy of nasopharyngeal carcinoma with transfer factor. Cancer Res. 1976;36(2 pt 2):720-3.
[96] Levine PH, Pizza H, Cannon G. et al. Transfer factor as an immunostimulator in nasopharyngeal carcinoma. Cancer Campaign. Nasopharyngeal Carcinoma. Eds Grundmann et al. Stuttgart; New York: Springer, 1988. Vol. 5: 137-68.
[97] Goldenberg GJ, Brandes LJ, Lau WH, Miller AB, Wall C, Ho JH. Cooperative trial of immunotherapy for nasopharyngeal carcinoma with transfer factor from donors with Epstein-Barr virus antibody activity. Cancer Treat Rep. 1985;69(7-8):761-7.
[98] Hancock BW, Bruce L, Sokol RJ, Clark A. Transfer factor in Hodgkin's disease: a randomized clinical and immunological study. Eur J Cancer Clin Oncol. 1988;24(5):929-33.
[99] Heinonen E, Grohn P, Tarkkanen J. Transfer factor in Hodgkin's disease: preliminary follow-up results. Immunolo­gy. 1985; 11: 73-9.
[100] Luk?cs K, K?vai M, Ber?nyi E, Frendl G, Schr?der I, Szegedi G. Effect of dialysable leukocyte extract on the mononuclear leukocytes in Hodgkin's disease. Haematologia (Budap). 1985;18(2):105-13.
[101] Mydill J. Transfer factor as an immunomodulator in Hodgkin's disease. Check. Pediatr. 1991; 46(5): 105-9.
[102] Corrado R, De Vinci C, Corrado G, Pizza G. Immunotherapy of renal cell carcinoma. Clinical and experimental develop­ ments. Eds F. M. G. Debruyne et al. Berlin: Springer, 1991: 105-26.
[103] Montie JE, Bukowski RM, James RE, Straffon RA, Stewart BH. A critical review of immunotherapy of disseminated renal adenocarcinoma. J Surg Oncol. 1982;21(1):5-8.
[104] Rosenberg AS, Lotze M, Maul LM et al. Transfer factor in disseminated adenocarcinoma. NEJM. 1987: 1223-1230.
[105] Pizza G, De Vinci C. Preliminary results in treatment of bladder cancer using Transfer factor III. Exp Pathol. 1987; 3: 335-41.
[106] Corrrado C, Pizza G et al. Transfer factor against the Bladder cancer. Exp Pathol. 1987: 347-53.
[107] Tarkkanen J, Grohn P, Heinonen E. Transfer factor (Dialy­ zable leukocyte extract) as an immunomodulator in urinary tract tumors. Cancer Immunol Immunother. 1989; 10: 251-5.
[108] Corrado F, Pizza G, de Vinci C, Corrado G. [Immunotherapy with transfer factor in hormone-resistant metastasized carcinoma of the prostate]. Arch Esp Urol. 1989;42 Suppl 2:191-6.
[109] Shaw MW, Ablin RJ, Guinan PD, Bhatti RA. Effect of transfer factor on tumor-associated immunity and tumor growth of the Dunning R-3327G rat prostate adenocarcinoma. Am J Reprod Immunol Microbiol. 1985;8(3):80-3.
[110] Vasily DB, Miller OF, Fudenberg HH, Goust JM, Wilson GB. Epidermodysplasia verruciformis: response to therapy with dialyzable leukocyte extract (transfer factor) derived from household contacts. J Clin Lab Immunol. 1984;14(1):49-57.
[111] De Bruy?re M, Cornu G, Heremans-Bracke T, Malchaire J, Sokal G. HLA haplotypes and long survival in childhood acute lymphoblastic leukaemia treated with transfer factor. Br J Haematol. 1980;44(2):243-51.
[112] Oettgen H, Old L, Farrow J. et al. Transfer factor in mastitis: a preliminary results I. Clin Invest. 1971; 50: 71-4.
[113] Smith GK, Morse PA, Deraps GD et al. Treatment of disseminant mastitis using specific and nonspecific Transfer factors. Surgery. 1973; 74: 59-63.
[114] Silverman MA, Meltz S, Sorokon C, Glade PR. Transfer Factor: basic properties and clinical applications. Eds M. S. Asher, A. A. Gottlieb, C. H. Kirkpatrick. New York: Acad, press, 1976: 23-41
[115] Vetto RM, Burger DR, Nolte JE, Vandenbark AA. Transfer Factor: basic properties and clinical applications. Eds M S. Asher, A. A. Gottlieb, C. H. Kirkpatrick. New York: Acad, press, 1976.: 118-30.